Morjaria, J B <br/><br/>
The role of a soluble TNFalpha receptor fusion protein (etanercept) in corticosteroid refractory asthma: a double blind, randomised, placebo controlled trial.  [electronic resource] 

 -  Thorax  Jul 2008 
 - 584-91 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1468-3296 
<br/><br/><label>Standard No.: </label>10.1136/thx.2007.086314  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Anti-Asthmatic Agents--therapeutic use<br/>Anti-Inflammatory Agents, Non-Steroidal--therapeutic use<br/>Asthma--drug therapy<br/>Biomarkers--blood<br/>Bronchial Hyperreactivity--physiopathology<br/>Double-Blind Method<br/>Drug Resistance<br/>Etanercept<br/>Female<br/>Forced Expiratory Volume--drug effects<br/>Humans<br/>Immunoglobulin G--therapeutic use<br/>Male<br/>Middle Aged<br/>Quality of Life<br/>Receptors, Tumor Necrosis Factor--therapeutic use<br/>Sputum--chemistry<br/>Surveys and Questionnaires<br/>Treatment Outcome<br/>Vital Capacity--drug effects